Gastrointestinal Organoid Biobank

Patient derived organoids (PDOs) are novel in vitro 3D cell models that preserve original tissue physiology and molecular pathology, thus representing a clinically-relevant alternative to traditional 2D cell lines and an effective tool to refine and reduce animal models. Merck are now offering a comprehensive biobank of highly characterised tissue-derived human gastrointestinal organoids from normal and diseased patients. Adult tissue derived organoids are phenotypically and genetically stable in long term culture, presenting more mature phenotypes compared to iPSC-derived organoids. Importantly, PDOs have shown to be able to predict patient clinical responses to chemotherapeutics.

The intestinal organoid biobank contains over 50 highly characterised intestinal organoids from both normal and diseased patients derived from multiple regions of the digestive systems including small intestine (duodenum, ileum), stomach, rectum and colon.

3dGRO™ organoids were derived utilising HUB Organoid Technology.

Biobank Overview

• 58 Patient Derived Organoid Samples
• Multiple Genders, Age, and Sex
• Multiple Tissues/Diseases: Colon, Duodenum, Ilium, Stomach, Rectum, Cancer, Ulcerative Colitis, IBS
• RNA-Seq Available
• Low Passage and High Viability
• Cultured in Optimised 3dGRO™ L-WRN Conditioned Media

Read More here.